(Q64383041)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

title

Comparison of the antitumor activity of bryostatins 1, 5, and 8 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

author name string

A S Kraft

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

S Woodley

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

G R Pettit

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

F Gao

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

J C Coll

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

F Wagner

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

language of work or name

English

0 references

publication date

1 January 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

14 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

page(s)

271-278

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00688328

14 October 2019

exact match

0 references

cites work

Effects of bryostatins 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells

1 reference

12 December 2020

Selective translocation of beta II-protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells

1 reference

12 December 2020

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

1 reference

12 December 2020

A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

1 reference

12 December 2020

In vivo administration of bryostatin 1, a protein kinase C activator, decreases murine resistance to Salmonella typhimurium

1 reference

12 December 2020

Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill

1 reference

12 December 2020

Successful treatment of murine melanoma with bryostatin 1.

1 reference

12 December 2020

Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity

1 reference

12 December 2020

Bryostatin induces changes in protein kinase C location and activity without altering c-myc gene expression in human promyelocytic leukemia cells (HL-60)

1 reference

12 December 2020

Effect of anti-TNF-alpha treatment in an antibiotic treated murine model of shock due to Streptococcus pyogenes

1 reference

12 December 2020

The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices

1 reference

12 December 2020

Demonstration of sub-nanomolar affinity of bryostatin 1 for the phorbol ester receptor in rat brain

1 reference

12 December 2020

Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells

1 reference

12 December 2020

Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.

1 reference

12 December 2020

Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists

1 reference

12 December 2020

Differential effects of bryostatins and phorbol esters on arachidonic acid metabolite release and epidermal growth factor binding in C3H 10T1/2 cells

1 reference

12 December 2020

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

1 reference

12 December 2020

Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody

1 reference

12 December 2020

Bryostatins selectively regulate protein kinase C-mediated effects on GH4 cell proliferation.

1 reference

12 December 2020

Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia

1 reference

12 December 2020

In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity

1 reference

12 December 2020

Potentiation of therapeutic effect of recombinant tumor necrosis factor against B16 mouse melanoma by combination with recombinant interleukin 2

1 reference

12 December 2020

Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer

1 reference

12 December 2020

Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts

1 reference

12 December 2020

Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models

1 reference

12 December 2020

Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00688328

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8529289%20AND%20SRC:MED&resulttype=core&format=json

14 October 2019

1 reference